Enrique C. Seoane-Vazquez, Ph.D.
Affiliations: | 2002 | University of Minnesota, Twin Cities, Minneapolis, MN |
Area:
Pharmacy, Public HealthGoogle:
"Enrique Seoane-Vazquez"Cross-listing: Econometree
Parents
Sign in to add mentor| Stephen W. Schondelmeyer | grad student | 2002 | UMN (Econometree) | |
| (Analysis of the patent life of new molecular entities approved by the FDA between 1980 and 2001.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Rodriguez-Monguio R, Seoane-Vazquez E, Powers JH. (2023) A Comparative Assessment of Approvals and Discontinuations of Systemic Antibiotics and Other Therapeutic Areas. Healthcare (Basel, Switzerland). 11 |
| Althobaiti H, Seoane-Vazquez E, Brown LM, et al. (2023) Disentangling the Cost of Orphan Drugs Marketed in the United States. Healthcare (Basel, Switzerland). 11 |
| Pham C, Le K, Draves M, et al. (2023) Assessment of FDA-Approved Drugs Not Recommended for Use or Reimbursement in Other Countries, 2017-2020. Jama Internal Medicine |
| Araujo L, Seoane-Vazquez E, Montagne M. (2021) Effect of free trade agreements on pharmaceutical market competition: The case of the 2009 US-Peru free trade agreement and its implementation as national drug policy. Health Policy Open. 2: 100039 |
| Ghanem B, Althobaiti H, Phillipe G, et al. (2020) PDG38 ASSESSMENT OF GENERIC COMPETITION FOR ORPHAN DRUGS MARKETED IN THE US (1993-2019) Value in Health. 23: S136 |
| Shukla V, Seoane-Vazquez E, Fawaz S, et al. (2019) The Landscape of Cellular and Gene Therapy Products: Cost, Approvals, and Discontinuations. Human Gene Therapy. Clinical Development |
| Zeukeng M, Seoane-Vazquez E, Bonnabry P. (2018) Response to the letter to the Editor regarding Zeukeng et al.'s article A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs. European Journal of Clinical Pharmacology. 74: 1199-1200 |
| Zeukeng M, Seoane-Vazquez E, Bonnabry P. (2018) A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs. European Journal of Clinical Pharmacology. 74: 811-818 |
| Kwon CS, Seoane-Vazquez E, Rodriguez-Monguio R. (2018) Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes. Bmc Health Services Research. 18: 78 |
| Almutairi R, Seoane-Vazquez E, Rodriguez-Monguio R. (2018) PRM262 - TRENDS IN DRUG PRICES BEFORE AND AFTER GENERIC COMPETITION IN THE US (2014-2016) Value in Health. 21: S401 |